Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N‑1H‑imidazol‑2‑yl‑N'‑[4‑(1H‑imidazol‑2‑ylamino)phenyl]benzene‑1,4-diamine is a synthetic small molecule with the molecular formula C18H17N7 and a molecular weight of 331.37 g/mol. It is listed in chemical and drug databases as an experimental compound but does not have an assigned pharmacological class or approved therapeutic use. Its mechanism of action, biological targets, clinical indications, and developer information are not available in public sources as of June 2025. The compound is referenced by several research identifiers (CHEMBL74371, DB08331), indicating it has been cataloged for potential screening or research purposes but lacks further characterization regarding its pharmacology or clinical development status[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-1H-imidazol-2-yl-N'-[4-(1H-imidazol-2-ylamino)phenyl]benzene-1,4-diamine.